Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis

Viera Janosova, Vladimir Calkovsky, Heiko Pedan, Estera Behanova, Andrej Hajtman, Andrea Calkovska, Viera Janosova, Vladimir Calkovsky, Heiko Pedan, Estera Behanova, Andrej Hajtman, Andrea Calkovska

Abstract

Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients' quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance. AR is treated by a combination of effective approaches; however, in some patients, the disease is uncontrolled. In the last several years, the concept of AR has shifted from increased T helper 2 (Th2) cell signaling and downstream inflammation to disease phenotypes with non-Th2-mediated inflammation. AR is a largely heterogenous group of airway diseases, and as such, research should not only focus on immunosuppressive agents (e.g., corticosteroids) but should also include targeted immunomodulatory pathways. Here, we provide an overview of novel therapies, focusing on the role of phosphodiesterase-4 (PDE4) inhibitors in AR. PDE4 inhibitors are potent anti-inflammatory agents that are used for the treatment of inflammatory airway diseases including AR. The PDE4 inhibitor roflumilast was shown to effectively control symptoms of AR in a randomized, placebo-controlled, double-blinded, crossover study in patients with a history of AR. However, only a few PDE4 inhibitors have proceeded to phase II and III clinical trials, due to insufficient clinical efficacy and adverse effects. Research is ongoing to develop more effective compounds with fewer side effects that target specific inflammatory pathways in disease pathogenesis and can provide more consistent benefit to patients with upper airway allergic diseases. Novel specific PDE4 inhibitors seem to fulfill these criteria.

Keywords: PDE4 inhibitor; T helper cells; allergic rhinitis; immunomodulation; inflammation.

Copyright © 2020 Janosova, Calkovsky, Pedan, Behanova, Hajtman and Calkovska.

References

    1. Apuhan T., Gepdiremen S., Arslan A. O., Aktas G. (2013). Evaluation of patients with nasal polyps about the possible association of desmosomal junctions, RORA and PDE4D Gene. Eur. Rev. Med. Pharmacol. Sci. 17 (9), 2680–2683.
    1. Brożek J. L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S., et al. (2017). Allergic rhinitis and its impact on asthma (ARIA) Guidelines—2016 Revision. J. Allergy Clin. Immunol. 140 (4), 950–958. 10.1016/j.jaci.2017.03.050
    1. Cao P. P., Shi L. L., Xu K., Yao Y., Liu Z. (2016). Dendritic cells in inflammatory sinonasal diseases. Clin. Exp. Allergy 46 (7), 894–906. 10.1111/cea.12755
    1. Cervin A., Lindgren S. (1998). The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro. Auris Nasus Larynx 25 (3), 269–276. 10.1016/S0385-8146(98)00010-8
    1. Chong S. N., Chew F. T. (2018). Epidemiology of allergic rhinitis and associated risk factors in Asia. World Allergy Organ. J. 11 (17), 4–21. 10.1186/s40413-018-0198-z
    1. Cilli A., Bal H., Gunen H. (2019). Efficacy and safety profile of roflumilast in a real-world experience. J. Thor. Dis. 11 (4), 1100–1105. 10.21037/jtd.2019.04.49
    1. Cingi C., Muluk N. B. (2020). All Around the Nose, Basic Science, Diseases and Surgical Management (Switzerland: Springer Nature; ).
    1. Contreras S., Milara J., Morcillo E., Cortijo J. (2017). Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: Current and futire evidences. Curr. Pharm. Des. 23 (14), 2073–2083. 10.2174/1381612822666160928112208
    1. Dahl R. (2006). Systemic side effects of inhaled corticosteroids in patients with asthma. Respir. Med. 100 (8), 1307–1317. 10.1016/j.rmed.2005.11.020h2
    1. Fokkens W. J., Lund V. J., Hopkins C., Hellings P. W., Kern R., Reitsma S., et al. (2020). European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58 (29), 1–464. 10.4193/Rhin20.600
    1. Gelfand E. W. (2004). Inflammatory mediators in allergic rhinitis. J. Allergy Clin. Immunol. 114 (5), S135–S138. 10.1016/j.jaci.2004.08.043
    1. Ghadersohi S., Tan B. K. (2017). Contemporary pharmacotherapy for allergic rhinitis and chronic rhinosinusitis. Otolaryngol. Clinics North America 50 (6), 1135–1151. 10.1016/j.otc.2017.08.009
    1. Gianello V., Salvi V., Parola C., Moretto N., Facchinetti F., Civelli M., et al. (2019). The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines , chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells. Biochem. Pharmacol. 163, 371–380. 10.1016/j.bcp.2019.03.006
    1. Graft D. F. (2000). New therapies for allergic rhinitis. Cleveland Clin. J. Med. 67 (3), 165–168. 10.3949/ccjm.67.3.165
    1. Heffler E., Brussino L., Del Giacco S., Paoletti G., Minciullo P. L., Varricchi G., et al. (2019). New drugs in early-stage clinical trials for allergic rhinitis. Expert Opin. Invest. Drugs 28 (3), 267–273. 10.1080/13543784.2019.1571581
    1. Howell M. D., Fitzsimons C., Smith P. A. (2018). JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. Ann. Allergy Asthma Immunol. 120 (4), 367–375. 10.1016/j.anai.2018.02.012
    1. Hox V., Lourijsen E., Jordens A., Aasbjerg K., Agache I., Alobid I., et al. (2020). Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: An EAACI position paper. Clin. Trans. Allergy 10 (1), 1–27. 10.1186/s13601-019-0303-6
    1. Keating G. M. (2017). Apremilast : A review in psoriasis and psoriatic arthritis. Drugs 77 (4), 459–472. 10.1007/s40265-017-0709-1
    1. Kosutova P., Mikolka P., Kolomaznik M., Balentova S., Adamkov M., Calkovska A., et al. (2018). Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury. Physiol. Res. 67, S645–S654. 10.33549/physiolres.934047
    1. Mokry J., Mokra D. (2013). Immunological aspects of phosphodiesterase inhibition in the respiratory system. Respir. Physiol. Neurobiol. 187 (1), 11–17. 10.1016/j.resp.2013.02.004
    1. Mokry J., Urbanova A., Kertys M., Mokra D. (2018). Inhibitors of phosphodiesterases in the treatment of cough. Respir. Physiol. Neurobiol. 257, 107–114. 10.1016/j.resp.2018.01.008
    1. Okano M. (2009). Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin. Exp. Immunol. 158 (2), 164–173. 10.1111/j.1365-2249.2009.04010.x
    1. Page C. P., Spina D. (2011). “Phosphodiesterase inhibitors in the treatment of inflammatory diseases,” in Phosphodiesterases as Drug Targets (Berlin Heidelberg: Springer-Verlag; ), 391–414. 10.1007/978-3-642-17969-3
    1. Parnham M. J., Nijkamp F. P., Rossi A. G. (2019). Principles of Immunopharmacology (Switzerland: Springer Nature; ).
    1. Pincelli C., Schafer P. H., French L. E., Augustin M., Krueger J. G. (2018). Mechanisms underlying the clinical effects of apremilast for psoriasis. J. Drugs Dermatol.: JDD 17 (8), 835–840. 10.5167/uzh-160510
    1. Price D., Smith P., Hellings P., Papadopoulos N., Fokkens W., Muraro A., et al. (2015). Current controversies and challenges in allergic rhinitis management. Expert Rev. Clin. Immunol. 11 (11), 1205–1217. 10.1586/1744666X.2015.1081814
    1. Ramamoorthy S., Cidlowski J. A. (2016). Corticosteroids. Mechanisms of action in health and disease. Rheum. Dis. Clinics North America 42 (1), 15–31. 10.1016/j.rdc.2015.08.002
    1. Ridolo E., Caminati M., Martignago I., Melli V., Salvottini C., Rossi O., et al. (2016). Expert review of clinical pharmacology allergic rhinitis: Pharmacotherapy in pregnancy and old age. Expert Rev. Clin. Pharmacol. 9 (8), 1081–1089. 10.1080/17512433.2016.1189324
    1. Schmidt B. M. W., Kusma M., Feuring M., Wehling M., Timmer W. E., Neuhäuser M., et al. (2001). The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 108 (4), 530–536. 10.1067/mai.2001.118596
    1. Singh D., Petavy F., Macdonald A. J., Lazaar A. L., O Connor B. J. (2010). The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir. Res. 11 (26), 1–9. 10.1186/1465-9921-11-26
    1. Singh D., Leaker B., Boyce M., Nandeuil M. A., Collarini S., Mariotti F., et al. (2016). A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. Pulm. Pharmacol. Ther. 40, 1–6. 10.1016/j.pupt.2016.06.011
    1. Singh D., Beeh K. M., Colgan B., Kornmann O., Leaker B., Watz H., et al. (2019). Effect of the inhaled PDE4 Inhibitor CHF6001 on biomarkers of inflammation in COPD. Respir. Res. 20 (180), 1–12. 10.1186/s12931-019-1142-7
    1. Skoner D. P. (2001). Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J. Allergy Clin. Immunol. 108 (1), 2–8. 10.1067/mai.2001.115569
    1. Sokol C. L., Barton G. M., Farr A. G., Medzhitov R. (2008). A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 9 (3), 310–318. 10.1038/ni1558
    1. Soto F. J., Hanania N. A. (2005). Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr. Opin. Pulm. Med. 11 (2), 129–134. 10.1097/01.mcp.0000151715.58124.9e
    1. Tabatabaian F., Casale T. B. (2018). Allergic rhinitis management: What’s next? Expert Rev. Clin. Immunol. 14 (3), 191–196. 10.1080/1744666X.2018.1438270
    1. Till S. J., Jacobson M. R., Brien F. O., Durham S. R., Kleinjan A., Fokkens W. J., et al. (2001). Recruitment of CD1a + Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy. Allergy 56 (2), 126–131. 10.1034/j.1398-9995.2001.056002126.x
    1. Urbanova A., Medvedova I., Kertys M., Mikolka P., Kosutova P., Mokra D., et al. (2017). Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs. Exp. Lung Res. 43 (9-10), 407–416. 10.1080/01902148.2017
    1. Woo T., Kuzel P. (2019). Crisaborole 2% ointment (Eucrisa) for atopic dermatitis. Skin Ther. Lett. 24 (2), 4–6.
    1. Zhang X., Chen Y., Fan L., Ye J., Fan J., Xu X., et al. (2018). Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap. Drug Des. Dev. Ther. 12, 2371–2379. 10.2147/DDDT.S165161
    1. Zheng T., Yu J., Oh M. H., Zhu Z. (2011). The atopic march: Progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol. Res. 3 (2), 67–73. 10.4168/aair.2011.3.2.67

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere